NEW SERVICES LAUNCH FOR CYPROTEX

Macclesfield-based drug testing company Cyprotex has announced the launch of a pair of new services which could help its customers to determine the usefulness of new products early in the development cycle.



The firm has launched PXR and AhR nuclear reception activation assets, which measures the reaction of nuclear receptors in the body to compounds. 



Cyprotex is also launching a Lysosomal Trapping service, which identifies the potential for certain drug compounds to become trapped within an acidic part of a body`s cells called the lysome.



Cyprotex`s chief scientific officer, Dr Katya Tsaioun, said: “Our knowledge of how certain drugs exhibit toxic effects is growing all the time.



”The latest additions to our growing suite of services further builds on our `fail early/fail cheaply` approach to drug discovery, which is aimed at saving both time and money for drug developers.”

You must be logged in to post a comment Login

Leave a Reply